港口生物Med 提交了第一阶段数据,表明HBM1020(一种潜在的抗抗性固态肿瘤新治疗方法)在2024年紧急管理业务办公室大会上具有有利的安全性和初步功效。 Harbour BioMed presented phase I data showing favorable safety and preliminary efficacy for HBM1020, a potential new treatment for resistant solid tumors, at ESMO Congress 2024.
在2024年ESMO大会上,港口生物Med介绍了关于HBM1020的新临床数据,HBM1020是完全人性反B7H7/HHLA2单克隆抗体。 Harbour BioMed presented new clinical data on HBM1020, a fully human anti-B7H7/HHLA2 monoclonal antibody, at ESMO Congress 2024. 第一阶段试验的结果显示,所有剂量的安全和耐用性都是有利的,大多数不利事件是温和的。 Results from a phase I trial indicated favorable safety and tolerability across all doses, with most adverse events being mild. 该药物展示了为期两周的消除半衰期,并显示出初步效果,46.7%的病人患上稳定疾病。 The drug demonstrated a two-week elimination half-life and showed preliminary efficacy, with 46.7% of patients achieving stable disease. HBM1020可以为有先进的固态肿瘤的病人,特别是那些抗PD-L1疗法的病人提供一种新的治疗选择。 HBM1020 may offer a new treatment option for patients with advanced solid tumors, especially those resistant to PD-L1 therapies.